BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute of Biomedical Engineering (BME)
X-ORIGINAL-URL:https://bme.utoronto.ca
X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220706T100000
DTEND;TZID=America/Toronto:20220706T110000
DTSTAMP:20260524T210633
CREATED:20220624T145430Z
LAST-MODIFIED:20220624T145508Z
UID:37746-1657101600-1657105200@bme.utoronto.ca
SUMMARY:Conversations in Convergence: Jesse Gillis\, PhD\, and Alaura Androschuk
DESCRIPTION:Note: We are excited to transition Conversations in Convergence from a virtual to an in-person event\, providing more opportunity for networking and potential collaboration. \nJoin us for our Conversations in Convergence series\, which features interactive discussions between Medicine by Design researchers who study similar questions using different approaches. \nThe theme of this conversation will be\, “Immune modulation by extrinsic and environmental factors.”\nRegister now \nSpeakers\nAlaura Androschuk \, PhD candidate in Michael Sefton’s lab\, Institute of Biomedical Engineering and the Department of Chemical Engineering & Applied Chemistry. \nIdentifying signalling pathways underlying biomaterial-driven terminal axon growth using single nucleus RNA-sequencing\nAlaura Androschuk is a PhD candidate focusing on the use of biomaterials for endogenous repair of tissues\, specifically subcutaneous nerve regeneration. Under the supervision of  Michael Sefton\, she has focused in part on identifying the signalling pathways and cells underlying the biomaterial-driven repair of complex tissues using proteomics and single nucleus transcriptomics. \nJesse Gillis\, Associate Professor and Bassingthwaighte Chair in Integrative Physiology\, Department of Physiology\, University of Toronto. \nBuffered and unbuffered cell lineage variability\nJesse Gillis completed his undergraduate in Biophysics at the University of Toronto\, where he also received his PhD in Neuroscience in 2007. His post-doctoral training was done at the Centre for High-throughput Biology at UBC. There\, he focused on meta-analysis of expression data\, and particularly co-expression analysis\, which infers functionality between genes based on shared expression profiles\, a form of network analysis. Jesse joined the faculty of CSHL in 2012 with a central focus on improving network analysis. In 2017\, he was promoted to Associate Professor at CSHL with his work focusing on single cell analysis\, particularly in collaboration with researchers in the BRAIN Initiative Cell Census Network. In 2022\, Jesse returned to U of T as the inaugural Bassingthwaighte Chair in Integrative Physiology and a Medicine by Design investigator. \nAbout Conversations in Convergence\nThe goal is to foster cross-disciplinary discussions in support of convergence\, which is the integration of approaches from engineering\, science\, medicine and other fields to expand knowledge and spark innovation. The researchers will discuss how their unique perspectives\, knowledge and ideas inform their work\, and how their diverse approaches intersect and complement one another to advance regenerative medicine.
URL:https://bme.utoronto.ca/event/conversations-in-convergence-jesse-gillis-phd-and-alaura-androschuk/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220707T140000
DTEND;TZID=America/Toronto:20220707T150000
DTSTAMP:20260524T210633
CREATED:20220624T143324Z
LAST-MODIFIED:20220624T151521Z
UID:37864-1657202400-1657206000@bme.utoronto.ca
SUMMARY:Faculty Search Candidate Talk - Unconventional Nanobiophotonics: Upconversion/Persistent Luminescence Nanoparticles for Anti-cancer Therapy
DESCRIPTION:Kai Huang\, PhD \nDepartment of Biochemistry and Molecular Biotechnology\nUniversity of Massachusetts Chan Medical School \nAbstract: Biophotonics has been widely applied as versatile and powerful approaches for biomedical applications\, such as for bioimaging\, biodetection\, photodynamic therapy\, and optogenetics. However\, conventional biophotonics suffers from several constraints. For example\, the short-wavelength excitation light cannot penetrate deep into the tissue\, thus requiring an invasive light delivery system for deep-tissue photodynamic therapy or optogenetics. In addition\, luminescence signal is interfered with autofluorescence noise\, bringing difficulties for high-quality bioimaging and biodetection. Here\, we address these issues by developing unconventional nanobiophotonics\, where we apply upconversion or persistent luminescence nanoparticles for anti-cancer therapy. Upconversion nanoparticles (UCNPs) convert near-infrared (NIR) excitation into short-wavelength visible light emission and thus serve as the light-transducer to bring deep tissue penetration NIR excitation for wireless photoactivations. We applied versatile nanoengineering approaches to produce UCNPs with controllable size/morphology\, tunable and enhanced luminescence\, and desirable biofunctionalizations. These UCNPs were applied for NIR-optogenetic control of CAR-T cell immunotherapy. We demonstrated that by wirelessly and spatiotemporally controlling the CAR-T cell activity\, we can achieve effective and safer immunotherapy of cancer\, overcoming the safety issue of conventional CAR-T immunotherapy. Persistent luminescence nanoparticles (PLNPs) are unique nanomaterials that emit long-lasting afterglow after excitation stops. PLNPs are significant for bioimaging by avoiding the autofluorescence induced by real-time excitation. We have developed the bottom-up syntheses of PLNPs with fine control of their energy traps\, heterostructures\, and energy accepting from dye-sensitizations\, contributing to enhanced persistent luminescence. We have demonstrated that PLNPs with enhanced luminescence are excellent for ultrasensitive imaging-guided tumor surgery. In addition\, we also demonstrated that by developing X-ray-excitable PLNPs\, we can achieve X-ray-photodynamic therapy with limitless tissue penetration and enhanced tumor eradication.
URL:https://bme.utoronto.ca/event/faculty-search-candidate-talk-2/
LOCATION:Medical Sciences Building 3154\, 1 King's College Cir\, Toronto\, Ontario\, M5S 1A8\, Canada
CATEGORIES:BME Faculty Search
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220710
DTEND;VALUE=DATE:20220714
DTSTAMP:20260524T210633
CREATED:20220510T202455Z
LAST-MODIFIED:20220510T202455Z
UID:36965-1657411200-1657756799@bme.utoronto.ca
SUMMARY:2022 TERMIS-AM Conference
DESCRIPTION:SUBMIT YOUR ABSTRACT HERE\n\n\n\nThe TERMIS-AM 2022 Conference will feature an outstanding scientific program bringing together national and international communities of scientists\, clinicians\, industry leaders\, post-doctoral fellows\, graduate students\, entrepreneurs\, and representatives of government funding agencies engaged in the fields of tissue engineering and regenerative medicine. \nPlease note\, there is no fee or charge to submit an abstract. \nIf you’ve submitted an abstract with TERMIS-AM before\, please use the same login information. You will need to make an account if you are new to the abstract system. \nClick HERE for COVID-19 Information \nAbstract Consideration\nExperts from academia\, industry and government are invited to present timely research to successful implementation of technologies in all areas of tissue engineering/regenerative medicine. \nNote: All abstract submitters including presenting authors are expected to pay their own travel expenses and conference registration fee(s). \nSUBMISSION INSTRUCTIONS \nAbstract Preparation\nAuthors must submit their abstract electronically. This is the ONLY option for abstract submission. \nTitle: Title should be brief\, clearly indicating the nature of the presentation. Title should be in bold font and mixed case font followed by a single return. Do not put a period at the end of the title.\nExample: This is a Properly Formatted Abstract Title \nCategory: Please select the TWIG category that your abstract falls under. You can select your primary\, secondary\, and tertiary preference for categories\, but only one is required. \nCategories: Please note sessions are slotted based on the number of abstracts submitted. \nBiofabrication & Bioreactors – TWIG\n+ Biofabrication and Software Tools in TERM\n+ Bioreactors and Organs-on-chips in TERM\n+ 3D Bioprinting Methods and Applications\nCardiovascular/Angiogenesis/Blood – TWIG\n+ Biomaterials for Endogenous Cardiovascular Repair\n+ Engineering Microvasculature for Tissue Regeneration\n+ Cell-based Approaches to Cardiac Regeneration & Repair\nCommercialization & Regulation – TWIG\n+ Regenerative Medicine Applications to Organ Transplantation Medicine\nDental & Craniofacial – TWIG\n+ Tissue Engineering Solutions for Craniofacial Regeneration\nImaging and Assessment – TWIG\n+ Non-invasive Imaging and Analysis of Engineered Tissues\nMusculoskeletal – TWIG\n+ ECM Technologies in Musculoskeletal Repair\n+ Regenerative Rehabilitation: Integrating Mechanical Stimulation with TERM\n+ Articular Cartilage Bioengineering & Regeneration\n+ Strategies for Regeneration of Complex Muscle Defects\nNeural & Spine – TWIG\n+ Frontiers in Spatiotemporal Control for Neural Tissue Engineering\nOphthalmologic – TWIG\n+ Cell Therapeutic Approaches for Retinal Degenerative Diseases\nRespiratory\, Urologic & Gastrointestinal – TWIG\n+ Respiratory\, Urologic\, & Gastrointestinal Tissue Engineering\n+ Tissue Repair for Voiding Dysfunction and Pelvic Floor Disorders\nScaffolds\, Matrices\, and Biomaterials – TWIG\n+ Biomaterials to Direct Stem Cell Fate\n+ Biomaterials for Women’s Health in Tissue Engineering\n+ Biomaterials and Immunomodulation\n+ Bio-metals Mediated Tissue Regeneration\n+ Nature as a Source of TERM Biomaterials and Strategies\n+ Bioactive Biomaterials for Soft Tissue Engineering\nStem Cells & Cell Therapies & Developmental Biology and Cell Signaling – TWIG\n+ Stem Cells & Cell Therapies\, Dev Bio\, and Cell Signaling\n+ Regeneration in the Context of Aging\nSkin\, Wound Healing\, and Inflammation – TWIG\n+ Skin\, Wound Healing\, and Inflammation\nOther\n+ 3D Tissue -Engineered Cancer/Disease Modeling and Organoids Part 1 & 2 \nAuthors: This is where you will enter your authors and it will be separate from your abstract body. Please enter information in the fields provided and the system with format it for you automatically. Complete contact information (name\, mailing address\, and e-mail) for each author listed on the abstract must be entered before submitting the abstract file. \nDisclosure Information: Submitting disclosures is a step when entering abstract authors. It will be the same step under each individual speaker. In order for your colleagues to properly evaluate the information\, analysis and opinions presented in your abstract\, it is important that they be informed of potential conflicts of interest pertinent to the research submitted. Therefore\, conference management requires that all authors provide any relevant information concerning personal or professional circumstances and relationships that might reasonably be expected to affect the author’s view on the subject. Examples include\, but are not limited to: \n+Stock options or bond holdings in a for-profit corporation or self-directed pension plan\n+Employment (full or part-time)\n+Ownership or partnership\n+Consulting fees or other remuneration (payment)\n+Non-remunerative positions of influence such as officer\, board member\, trustee\, or public spokesperson\n+Receipt of royalties\n+Speakers bureau \nAppropriate disclosure will be stated in the scientific program and the abstract volume. If you do not have anything to disclose\, you must indicate this on the online abstract submission form. The disclosure information you provide will not influence the review of your abstract. Abstracts will not be reviewed without proper completion of the disclosure section on the abstract submission form. Disclosure information for all authors is required upon abstract completion. \nAbstract: The abstract should clearly describe the nature of the research and the problem it addresses and be presented in such language as to be understood by scientists representing the multi-disciplinary nature of tissue engineering. The abstract should summarize the purpose/objective of the research\, the methodology employed\, the results\, and the conclusion/significance and will be split into these four categories. \n\nThe abstract length is limited to 500 words total across all four sections. These areas should not include authors\, disclosures\, or references.\nPlease no figures or tables in the abstract.\nReferences and acknowledgements are not needed in this abstract process.\n\nPresentation Preference: Please choose your preferred method of presentation (Oral\, Poster\, or Oral or Poster) where indicated. Your preference will be noted by the reviewers. Final determination will be made by the Program Planning Committee. \nPublication: Abstracts this year will be published on the TERMIS-AM website or in the journal. Here you can choose to opt-out of publication. \nDemographics: You can select if you are a Student or Young Investigator here. Please fill out the other demographic information if you feel comfortable. These questions help us promote diversity within our abstract presenters. \nReview My Work: Here you will see a green check mark if all steps have been completed or not and you will have to go back and make edits. Your submission is not complete unless you see a green check mark. You are able to make edits to your abstract until the deadline of January 12\, 2021\, 11:59 PM Pacific Time. Once the abstract deadline has passed\, no further edits can or will be made to an abstract. \nAbstract Withdrawals \nIf the abstract must be withdrawn\, the TERMIS-AM office must be notified in writing at least ONE month prior to the meeting via e-mail to Tatiana Veres at am2022@termis.org \nNOTE: ALL PRESENTERS ARE EXPECTED TO COVER THEIR OWN TRAVEL AND LODGING EXPENSES AND PAY THE CONFERENCE REGISTRATION FEES. \nRegistration Requirements \nAccepted authors are expected to pay their own travel expenses and conference registration fee(s). Dates of presentation cannot be guaranteed. \n\nSUBMIT YOUR ABSTRACT HERE\n\nFor More Information \nFor more information on abstract content\, format and submission procedure\, contact: \nTatiana Veres\nAssociate Meeting Manager\nam2022@termis.org
URL:https://bme.utoronto.ca/event/2022-termis-am-conference/
CATEGORIES:Events & Workshops
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220710T130000
DTEND;TZID=America/Toronto:20220710T160000
DTSTAMP:20260524T210633
CREATED:20220628T150838Z
LAST-MODIFIED:20220628T150838Z
UID:37908-1657458000-1657468800@bme.utoronto.ca
SUMMARY:TERMIS-AM/ NSERC CREATE Training Program in Organ-on-a-Chip Engineering and Entrepreneurship Per-conference Workshop
DESCRIPTION:https://toep.utoronto.ca/ \nNSERC CREATE Training Program in Organ-on-a-Chip & Entrepreneurship (TOeP) is organizing a pre-conference workshop geared towards inspiring trainees to engage into a process of taking their discovery out of the lab and into the real world. \n  \nUniquely\, our workshop speakers were all (or still are) trainees who haven commercialized the discoveries from their PhD or Post-doctoral training through a start-up company. They were instrumental in growing these companies and have valuable lessons to share to facilitate the journey. \n  \nAt the end of this workshop\, you will be able to: understand how to identify the novel components of your work\, improve problem-based design in tissue engineering and regenerative medicine\, understand the steps toward commercialization of devices and cell based therapeutics and what elements to include in a successful pitch. \n  \nNSERC CREATE TOeP Training program will reimburse the workshop registration fee for the first 30 trainees who register. Reimbursement forms will be available at the workshop.  \n  \nProgram: \nSunday July 10th\, 2022 \n1:00PM-1:20PM      Milica Radisic\, Professor and Canada Research Chair (Tier 1) in Organ-on-a-Chip Engineering\, University of Toronto; Senior Scientist\, Toronto General Research Institute; Director\, NSERC CREATE Training Program in Organ-on-a-Chip Engineering and entrepreneurship. www.radisiclab.com \n“Introduction to the goals of the workshop”  \n  \n1:20PM-1:40PM      Anis Hadjenni- CEO and Co-founder\, Rheolution Inc\, https://rheolution.com/ \n“From an idea to a successful company- the story of Rheolution”                                                                \n1:40PM-2:00PM      Wendy Neimark\, Co-founder and Chief Technology Officer\, Ripple Therapeutics\, www.rippletherapeutics.com \n“Assessing the novelty of your idea\, the story of Ripple”                                                                \n2:00PM-2:20PM      Milica Vukmirovic\, Director of External Programs & Partnerships\, Precision Medicine Initiative\, PRiME\, University of Toronto\, https://www.prime.utoronto.ca/ \n“Developing a pitch and setting your idea for successful fundraising”                                                               \n2:20PM-3:00PM      Networking break \n  \n3:00PM-3:20PM      Sepand Bafti\, Director of Biological Science at Nortis \n “Working to grow your organ-on-a-chip startup”          https://nortisbio.com/                                                              \n3:20PM-3:40PM      Dawn Lin\, PhD Candidate at McMaster University & Co-founder Organo-Biotech\, https://www.organo-biotech.com/ \n“Trainee perspective- starting a company during your PhD”                                                                         \n3:40PM-4:00PM      Mohsen Akbari\, Associate Professor\, University of Victoria\, https://www.uvic.ca/ecs/mechanical/faculty-and-staff/faculty/makbari.php \n“PI perspective on starting a company from the lab”                                                  \n  \nAbout NSERC CREATE TOeP: \nThe long-term objective of TOeP is to educate skilled individuals with expertise in both bioengineering and entrepreneurship\, and enable personal development of our students so that they can ultimately fuel the creation of a high-tech economy. \nTOeP provides specific workshops for Professional Skill Training in the following categories: Pitching and public speaking; IP Law; Entrepreneurship; Networking and business etiquette; Teamwork\, critical thinking\, leadership & project management; Business and Finance.  TOeP provides technical training through an Organ-on-a-Chip Course\, TOeP specific guest speaker seminars and Ontario-on-a-Chip/TOeP Annual Symposium which features a TOeP student pitch competition. \nTOeP provides coaching to the students for pitch development and practice sessions to perfect those. To reach a broader scientific community TOeP also organizes the Entrepreneurship Workshop at the meetings such as this one. \nTOeP trainees are required to complete exchanges with other academic labs\, in order to satisfy the mobility required for the program\,  shadow entrepreneurs\, develop their device prototypes and fundraise for commercialization of their prototypes either via VCs\, angels and private investors or through grants.
URL:https://bme.utoronto.ca/event/termis-am-nserc-create-training-program-in-organ-on-a-chip-engineering-and-entrepreneurship-per-conference-workshop/
CATEGORIES:Events & Workshops
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220721T100000
DTEND;TZID=America/Toronto:20220721T110000
DTSTAMP:20260524T210633
CREATED:20220719T155334Z
LAST-MODIFIED:20220719T155334Z
UID:38182-1658397600-1658401200@bme.utoronto.ca
SUMMARY:Nanomedicines for the Research\, Detection\, and Treatment of Cancer and Allied Diseases
DESCRIPTION:Date: Thursday July 21\, 2022 \nTime: 10:00am – 11:00am \nLocation: Donnelly Centre \n160 College Street\, 2nd Floor\, Red Seminar Room \n  \nDr. Daniel A. Heller\, PhD Cornell University \n  \nAbstract \nWe develop nanotechnologies to accelerate the research\, diagnosis\, and treatment of cancer and allied diseases. We focus on nanoparticle drug delivery systems and nanosensor-based diagnostics and drug discovery tools. \nTo build better cancer therapeutics\, we investigate the potential to improve the therapeutic index of precision medicines via nanomedicine-based strategies to localize drugs to tumors using vascular targets. We developed machine learning processes to facilitate the encapsulation of diverse drug classes into these nanoparticles\, based on drug molecular structure\, resulting in the rapid synthesis of many\, diverse\, targeted nanotherapeutics. We found that P-selectin\, expressed endogenously on activated endothelium in tumors\, can be used as a nanotherapeutic target improve the efficacy of kinase inhibitors and abrogate dose-limiting toxicities\, to improve therapeutic index. P-selectin can also be induced via ionizing radiation\, enabling the enhancement of the target. We also found that endothelial targeting can improve delivery across intact blood-brain barrier for the treatment of intracranial tumors and metastases\, via activating transendothelial transport. \nWe also develop optical nanosensor technologies using carbon nanotubes to facilitate longitudinal detection of cancer biomarkers\, and to build new assays for cancer drug development. These technologies employ the bandgap fluorescence of single-walled carbon nanotubes (SWCNTs) which emit in the near-infrared “tissue transparent” window and can respond to analytes down to the single-molecule level. We have developed new sensors for the detection of metabolic changes in live cells and tissues\, disease biomarkers in situ via implants\, and overall disease states\, aided by machine learning processes. \nBiography \nDr. Daniel A. Heller\, PhD\, is Head of the Cancer Nanomedicine Laboratory\, Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chair\, an Associate Member in the Molecular Pharmacology Program at Memorial Sloan-Kettering Cancer Center\, an Associate Professor in the Department of Pharmacology at Weill Cornell Medicine\, and a member of the Graduate Field Faculty in the Meinig School of Biomedical Engineering at Cornell University. His \nwork focuses on the development of nanoscale technologies for the treatment\, diagnosis\, and research of cancer. Dr. Heller obtained his PhD in chemistry from the University of Illinois at Urbana-Champaign in 2010\, working in the laboratory of Michael Strano. He completed a Damon Runyon Cancer Research Foundation Postdoctoral Fellowship in the laboratory of Robert Langer at the David H. Koch Institute for Integrative Cancer Research at MIT in 2012. He is a 2012 recipient of the National Institutes of Health Director’s New Innovator Award\, a 2015 Kavli Fellow\, a 2017 recipient of the Pershing Square Sohn Prize for Young Investigators in Cancer Research\, a 2018 American Cancer Society Research Scholar\, a 2018 recipient of the CRS Nanomedicine and Nanoscale Drug Delivery Focus Group Junior Faculty Award\, a 2018 NSF CAREER Awardee\, a 2020 awardee of the Weill Cornell Graduate School Pharmacology Teaching and Mentoring Award\, and a 2021 American Institute for Medical and Biological Engineering (AIMBE) Fellow. \n\nHosted by Dr. Molly Shoichet \nSnacks and refreshments will be served
URL:https://bme.utoronto.ca/event/nanomedicines-for-the-research-detection-and-treatment-of-cancer-and-allied-diseases/
LOCATION:Donnelly Centre for Cellular and Biomolecular Research\, Red Room\, 160 College Street\, Toronto\, Ontario\, M5S 3E1\, Canada
CATEGORIES:External Speaker Series
END:VEVENT
END:VCALENDAR